- Home
- BWFG vs YMAB Comparison
BWFG vs YMAB Comparison
Compare BWFG & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWFG
- YMAB
- Stock Information
- Founded
- BWFG 2002
- YMAB 2015
- Country
- BWFG United States
- YMAB United States
- Employees
- BWFG N/A
- YMAB N/A
- Industry
- BWFG Major Banks
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- BWFG Finance
- YMAB Health Care
- Exchange
- BWFG Nasdaq
- YMAB Nasdaq
- Market Cap
- BWFG 231.9M
- YMAB 270.5M
- IPO Year
- BWFG N/A
- YMAB 2018
- Fundamental
- Price
- BWFG $30.13
- YMAB $4.81
- Analyst Decision
- BWFG Buy
- YMAB Buy
- Analyst Count
- BWFG 1
- YMAB 11
- Target Price
- BWFG $40.00
- YMAB $18.73
- AVG Volume (30 Days)
- BWFG 15.7K
- YMAB 349.7K
- Earning Date
- BWFG 04-23-2025
- YMAB 03-04-2025
- Dividend Yield
- BWFG 2.65%
- YMAB N/A
- EPS Growth
- BWFG N/A
- YMAB N/A
- EPS
- BWFG 1.23
- YMAB N/A
- Revenue
- BWFG $64,379,999.00
- YMAB $87,685,000.00
- Revenue This Year
- BWFG $57.98
- YMAB $20.07
- Revenue Next Year
- BWFG $12.49
- YMAB $8.76
- P/E Ratio
- BWFG $24.50
- YMAB N/A
- Revenue Growth
- BWFG N/A
- YMAB 3.38
- 52 Week Low
- BWFG $22.47
- YMAB $4.25
- 52 Week High
- BWFG $35.25
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- BWFG 48.94
- YMAB 40.82
- Support Level
- BWFG $30.13
- YMAB $4.65
- Resistance Level
- BWFG $30.85
- YMAB $5.32
- Average True Range (ATR)
- BWFG 0.68
- YMAB 0.30
- MACD
- BWFG 0.12
- YMAB 0.07
- Stochastic Oscillator
- BWFG 69.36
- YMAB 41.38
About BWFG Bankwell Financial Group Inc.
Bankwell Financial Group Inc is a bank holding company, engaged in providing financial products and services. It offers products related to commercial lending, retail lending, depository services, and others. The bank's commercial lending products includes owner-occupied commercial real estate loans, commercial real estate investment loans, commercial loans to small and mid-sized businesses and real estate construction and development loans. The retail lending products include residential mortgage loans, home equity lines of credit, and consumer installment loans. Its depository products include checking, savings, money market, certificates of deposit, noninterest-bearing demand, and time deposits.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.